Hengrui and Kailera have been vocal about positioning the drug as being capable of improving the clinical profile of existing ...

It’s exciting news in an orphan indication which currently lacks any approved treatment, and Dr Hans Lee, director of ...

At the moment, many of the big AI systems used in drug discovery are closed-source, meaning they are proprietary and carry an ...

The EU is asking for feedback on measures proposed by Sanofi to address concerns about a marketing campaign for a flu vaccine ...

In another big-ticket licensing deal with a Chinese biotech, AstraZeneca has claimed rights to a drug candidate for chronic ...

Marcus Evans announces The Evolution Summit, taking place September 28-29, 2026, at Park Hyatt Aviara Resort, Golf Club & Spa ...

Vera Therapeutics has won FDA approval for Trutakna, a BAFF/APRIL inhibitor for IgA nephropathy (IgAN) that will compete with ...

Andrew Witty had been CEO of UnitedHealth Group for four years. Andrew Witty has resigned as chief executive of US health conglomerate UnitedHealth Group, as the company pulled its financial forecasts ...

Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline weight-loss result has sent its shares into a sharp decline. The stock was ...

Roche has posted a mixed set of data from two clinical trials of its anti-IL-33/ST2 antibody astegolimab in chronic obstructive pulmonary disease (COPD), casting a shadow over the programme. On the ...

In its first meeting for months, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted against AstraZeneca's oral selective oestrogen receptor degrader (SERD) drug camizestrant. By a margin of six ...

Amgen has reported encouraging mid-stage results for its olpasiran candidate for reducing lipoprotein(a) – a risk factor for atherosclerotic cardiovascular disease – and now plans to move ahead ...